[go: up one dir, main page]

BRPI0508961A - derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão - Google Patents

derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão

Info

Publication number
BRPI0508961A
BRPI0508961A BRPI0508961-1A BRPI0508961A BRPI0508961A BR PI0508961 A BRPI0508961 A BR PI0508961A BR PI0508961 A BRPI0508961 A BR PI0508961A BR PI0508961 A BRPI0508961 A BR PI0508961A
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
hypertension
treatment
methylnonamide
Prior art date
Application number
BRPI0508961-1A
Other languages
English (en)
Inventor
Peter Herold
Stefan Atutz
Robert Mah
Vincenzo Tschinke
Aleksandar Stojanovic
Nathalie Jotterand
Michael Quirmbach
Dirk Behnke
Christiane Marti
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of BRPI0508961A publication Critical patent/BRPI0508961A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DE 5-AMINO-4-HIDRóXI-7-(1H-INDOLMETIL)-8-METILNONAMIDA COMO INIBIDORES DE RENINA PARA O TRATAMENTO DE HIPERTENSãO. A presente invenção refere-se a novas alquilamidas da fórmula geral (I), onde X é -CH~ 2~- ou > CH-OH; (A)R¬ 1¬ é, por exemplo, um radical heterociclila opcionalmente substituído ou um radical hidrcarboneto insaturado, policíclico opcionalmente substituído, onde X é hidroximetileno; R¬ 2¬ é C~ 1~-C~ 6~-alquila ou C~ 1~-C~ 6~-cicloalquila; R¬ 3¬ são, cada um, independentemente, H, C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alcoxicarbonila ou C~ 1~-C~ 6~-alcanoíla; R¬ 4¬ é C~ 1~-C~ 6~-alquila, C~ 3~-C~ 6~-cicloalquila, C~ 2~C~ 6~-alquenila ou aril-C~ 1~-C~ 6~-alquila substituída ou não substituída; R¬ 5¬ é C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-hidroxialquila, C~ 1~-C~ 6~-alcóxi-C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alcanoilóxiC~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-aminoalquila, C~ 1~-C~ 6~-alquilamino-C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-dialaquilamino-C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alcanoilamido-C~ 1~-C~ 6~-alquila, HO(O)C-C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alquil-O-(O)C-C~ 1~-C~ 6~-alquila, H~ 2~N-C(O)-C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alquil-HN-C(O)-C~ 1~-C~ 6~-alquila, (C~ 1~-C~ 6~-alquil)~ 2~N-C(O)-C~ 1~-C~ 6~-alquila, C~ 2~-C~ 8~-alquenila, C~ 2~-C~ 8~-alquinila, ciano-C~ 1~-C~ 6~-alquila, halo-C~ 1~-C~ 6~-alquila, aril-C~ 0~ -C~ 6~-alquila opcionalmente substituída, C~ 3~C~ 8~-cicloalquil-C~ 0~-C~ 6~-alquila opcionalmente substituída ou heterociclil-C~ 0~-C~ 6~-alquila opcionalmente substituída; a um processo para sua preparação e ao uso destes compostos como medicamentos, especialmente como inibidores de renina para o tratamento de hipertensão.
BRPI0508961-1A 2004-03-19 2005-03-17 derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão BRPI0508961A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4692004 2004-03-19
PCT/EP2005/051244 WO2005090305A1 (en) 2004-03-19 2005-03-17 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension

Publications (1)

Publication Number Publication Date
BRPI0508961A true BRPI0508961A (pt) 2007-08-14

Family

ID=34963284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508961-1A BRPI0508961A (pt) 2004-03-19 2005-03-17 derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão

Country Status (15)

Country Link
US (1) US7851634B2 (pt)
EP (4) EP1712548A3 (pt)
JP (1) JP2007529474A (pt)
CN (1) CN1934083A (pt)
AR (1) AR048320A1 (pt)
AT (1) ATE421501T1 (pt)
BR (1) BRPI0508961A (pt)
CA (1) CA2560199A1 (pt)
DE (1) DE602005012481D1 (pt)
ES (1) ES2320030T3 (pt)
IL (1) IL178100A0 (pt)
PL (1) PL1717226T3 (pt)
PT (1) PT1717226E (pt)
TW (1) TW200536539A (pt)
WO (1) WO2005090305A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
WO2007031558A1 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
PT2420491E (pt) 2005-12-30 2013-10-14 Novartis Ag Compostos de piperidina 3,5-substituída como inibidores de renina
JP2009525304A (ja) * 2006-01-30 2009-07-09 シュペーデル・エクスペリメンタ・アーゲー α，β−不飽和化合物からのアルコールの立体選択的製造方法
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
EP1911762A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
EP1921069A1 (de) * 2006-11-08 2008-05-14 Speedel Experimenta AG Verfahren zur Herstellung von 2-Alkyl-3-heterocyclyl-prop-2-en-1-olen
EP1939182A1 (de) * 2006-12-22 2008-07-02 Speedel Experimenta AG Verfahren zur Herstellung von (R oder S)-2-Alkyl-3-heterocyclyl-1-propanolen
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
CA2689109A1 (en) 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
WO2011051853A1 (en) 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
AU2001270025B2 (en) * 2000-06-21 2005-08-18 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20060154926A1 (en) * 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides

Also Published As

Publication number Publication date
TW200536539A (en) 2005-11-16
PL1717226T3 (pl) 2009-07-31
EP1712548A2 (en) 2006-10-18
IL178100A0 (en) 2006-12-31
CA2560199A1 (en) 2005-09-29
EP1699762A1 (en) 2006-09-13
JP2007529474A (ja) 2007-10-25
EP1717226B1 (en) 2009-01-21
AR048320A1 (es) 2006-04-19
ATE421501T1 (de) 2009-02-15
EP1712548A3 (en) 2006-11-02
WO2005090305A1 (en) 2005-09-29
US7851634B2 (en) 2010-12-14
EP1724259A1 (en) 2006-11-22
DE602005012481D1 (de) 2009-03-12
EP1717226A1 (en) 2006-11-02
CN1934083A (zh) 2007-03-21
US20080280895A1 (en) 2008-11-13
PT1717226E (pt) 2009-04-03
ES2320030T3 (es) 2009-05-18

Similar Documents

Publication Publication Date Title
BRPI0508961A (pt) derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão
BRPI0713446B8 (pt) compostos inibidores de prolil hidroxilase, composição farmacêutica compreendendo os mesmos, usos terapêuticos destes e processo para preparar a dita composição
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
ECSP066667A (es) Derivados de ciclohexano espirociclicos
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
ATE451351T1 (de) Vitamin-d-analogon nel, verfahren und seine verwendung
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EA200401378A1 (ru) N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
BRPI0413565A (pt) análogos de quinazolina como inibidores de receptor de tirosina quinase
BRPI0416039A (pt) derivados de tiazol e pirazol como inibidores de flt-3 cinase
BR112021018692A2 (pt) 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
Şöhretoğlu et al. In vitro and in silico assessment of DNA interaction, topoisomerase I and II inhibition properties of chrysosplenetin
Jan et al. Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity
WO2003007883A3 (en) Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
ATE401080T1 (de) (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
MXPA04008926A (es) Inhibidores de entrada a moleculas pequenas.
ATE364384T1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.